About: Clinical characteristics of liver failure with hemophagocytic lymphohistiocytosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical characteristics of liver failure with hemophagocytic lymphohistiocytosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical characteristics of liver failure with hemophagocytic lymphohistiocytosis
Creator	Li, Juan Yu, Hongwei Hu, Zhongjie Xie, Fang Dong, Jinling Jia, Lin Meng, Qinghua Yao, Qinwei Zhao, Yujuan Zhu, Yueke
Source	PMC
abstract	Liver failure with hemophagocytic lymphohistiocytosis (HLH) is a life-threatening syndrome with high mortality. The aim of this study was to decipher clinical and laboratory characteristics of hemophagocytic lymphohistiocytosis after definite diagnosis of liver failure and to provide clues for early diagnosis and treatment of HLH in patients with liver failure. Eleven patients diagnosed with liver failure and HLH were retrospectively investigated in this study. All patients presented with jaundice, persistent high-grade fever, pancytopenia, splenomegaly, evidence of hemophagocytes in the bone marrow and laboratory abnormalities indicating HLH. The average interval from the earliest diagnosis of liver failure to a definitive diagnosis of HLH was 17.27 days. Six (54.55%) patients died during follow-up. For patients with liver failure after admission and subsequently definitively diagnosed with HLH, bilirubin and INR were significantly decreased. HLH is definitely diagnosed at an intermediate or late stage when patients have already suffered from liver failure. The initial dose of glucocorticoid (methylprednisolone) was decreased to 1–1.5 mg/kg/d and gradually reduced thereafter. In conclusion, for patients with liver failure, HLH should be screened as early as possible upon persistent fever, splenomegaly and unexplained pancytopenia. For patients with liver failure and HLH, the dosage of glucocorticoid should be reduced to avoid serious side effects.
has issue date	2019-05-31(xsd:dateTime)
bibo:doi	10.1038/s41598-019-43909-w
bibo:pmid	31148551
has license	cc-by
sha1sum (hex)	5928db30526f18fa51e7e0aebc5cad6327cf37ac
schema:url	https://doi.org/10.1038/s41598-019-43909-w
resource representing a document's title	Clinical characteristics of liver failure with hemophagocytic lymphohistiocytosis
has PubMed Central identifier	PMC6544643
has PubMed identifier	31148551
schema:publication	Sci Rep
resource representing a document's body	covid:5928db30526f18fa51e7e0aebc5cad6327cf37ac#body_text
is schema:about of	named entity 'splenomegaly' named entity 'indicating' named entity 'liver failure' named entity 'patients' named entity 'abnormalities' named entity 'methylprednisolone' named entity 'mortality' named entity 'aim' named entity 'hemophagocytic lymphohistiocytosis' named entity '1.5' named entity 'CONCLUSION' named entity 'DAYS' named entity 'SYNDROME' named entity 'REDUCED' named entity 'MORTALITY' named entity 'bilirubin' named entity 'screened' named entity 'evidence' named entity 'diagnosis' named entity 'laboratory' named entity 'patients' named entity 'days' named entity 'jaundice' named entity 'fever' named entity 'HLH' named entity 'jaundice' named entity 'early diagnosis' named entity 'liver failure' named entity 'glucocorticoid' named entity 'HLH' named entity 'splenomegaly' named entity 'follow-up' named entity 'bilirubin' named entity 'pancytopenia' named entity 'liver failure' named entity 'hemophagocytic lymphohistiocytosis' named entity 'fever' named entity 'liver failure' named entity 'splenomegaly' named entity 'hemophagocytic lymphohistiocytosis' named entity 'Clinical characteristics' named entity 'blood cell counts' named entity 'etoposide' named entity 'Beijing, China' named entity 'fever' named entity 'gastrointestinal symptoms' named entity 'Institutional Review Board' named entity 'type 2 diabetes' named entity 'liver failure' named entity 'septic shock' named entity 'adverse event' named entity 'fatigue' named entity 'NK-cell' named entity 'Capital Medical University' named entity 'fever' named entity 'gene' named entity 'median age' named entity 'methylprednisolone' named entity 'glucocorticoid' named entity 'drug-induced' named entity 'splenomegaly' named entity 'fludarabine' named entity 'acute liver failure' named entity 'Hypertriglyceridemia' named entity 'IL-2 receptor' named entity 'liver failure' named entity 'prognosis' named entity 'liver function' named entity 'jaundice' named entity 'plasma exchange' named entity 'liver failure' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software